BioForce Nanosciences Net debt/EBITDA
Mi az BioForce Nanosciences Net debt/EBITDA?
A Net debt/EBITDA az BioForce Nanosciences Holdings, Inc. - -13.80
Mi a Net debt/EBITDA meghatározása?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA a Consumer Staples szektor a OTC-on cégekben a BioForce Nanosciences -hoz képest
Mit csinál BioForce Nanosciences?
BioForce Nanosciences Holdings, Inc. focuses on providing natural vitamins, minerals, other nutritional supplements, powders, and beverages for individuals in various age ranges. The company offers private label products with distributors and manufacturing providers. It sells its nutrition supplements to retailers, sporting goods retailers, supermarkets, and mass merchandisers under the BioForce Eclipse brand, as well as through online and telemarketing. The company is based in Virginia Beach, Virginia.
net debt/ebitda -hoz hasonló cégek BioForce Nanosciences
- Isabella Bank nak Net debt/EBITDA -13.86 van
- Sinosoft Technology nak Net debt/EBITDA -13.85 van
- Capita Plc nak Net debt/EBITDA -13.84 van
- EGL nak Net debt/EBITDA -13.82 van
- Atlas Pearls Ltd nak Net debt/EBITDA -13.82 van
- Excelsior Mining nak Net debt/EBITDA -13.81 van
- BioForce Nanosciences nak Net debt/EBITDA -13.80 van
- Greenbrook TMS nak Net debt/EBITDA -13.79 van
- Neogenomics nak Net debt/EBITDA -13.78 van
- Onto Innovation nak Net debt/EBITDA -13.78 van
- CBTX Inc nak Net debt/EBITDA -13.76 van
- Christopher & Banks nak Net debt/EBITDA -13.75 van
- Patagonia Gold nak Net debt/EBITDA -13.74 van